BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25911624)

  • 1. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors.
    Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P
    Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
    Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y
    Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
    Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
    Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.
    Yang J; Su G; Ren Y; Chen Y
    Eur J Med Chem; 2015 Aug; 101():41-51. PubMed ID: 26114810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
    Wang Y; Sun X; Yang D; Guo Z; Fan X; Nie M; Zhang F; Liu Y; Li Y; Wang Y; Gong P; Liu Y
    Bioorg Med Chem; 2016 Nov; 24(21):5646-5661. PubMed ID: 27663548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative Three-Step Microwave-Promoted Synthesis of
    Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.
    Xing J; Yang L; Li H; Li Q; Zhao L; Wang X; Zhang Y; Zhou M; Zhou J; Zhang H
    Eur J Med Chem; 2015 May; 95():388-99. PubMed ID: 25839438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.
    Xue T; Ding S; Guo B; Zhou Y; Sun P; Wang H; Chu W; Gong G; Wang Y; Chen X; Yang Y
    J Med Chem; 2014 Sep; 57(18):7770-91. PubMed ID: 25179681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
    Xing J; Yang L; Yang Y; Zhao L; Wei Q; Zhang J; Zhou J; Zhang H
    Eur J Med Chem; 2017 Jan; 125():411-422. PubMed ID: 27689724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fucosylated chondroitin sulfate oligosaccharides exert anticoagulant activity by targeting at intrinsic tenase complex with low FXII activation: Importance of sulfation pattern and molecular size.
    Li J; Li S; Yan L; Ding T; Linhardt RJ; Yu Y; Liu X; Liu D; Ye X; Chen S
    Eur J Med Chem; 2017 Oct; 139():191-200. PubMed ID: 28800457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and evaluation of isoxazolo[5,4-d]pyrimidin-4(5H)-one derivatives as antithrombotic agents.
    Yang J; Su G; Ren Y; Chen Y
    Bioorg Med Chem Lett; 2015 Feb; 25(3):492-5. PubMed ID: 25559742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
    Orwat MJ; Qiao JX; He K; Rendina AR; Luettgen JM; Rossi KA; Xin B; Knabb RM; Wexler RR; Lam PY; Pinto DJ
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3341-5. PubMed ID: 24951330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system.
    Ishihara T; Koga Y; Iwatsuki Y; Hirayama F
    Bioorg Med Chem; 2015 Jan; 23(2):277-89. PubMed ID: 25523211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
    Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T
    Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition.
    Zhu Y; Lin Y; Liu X; Hu W; Wang Y
    Biochem Biophys Res Commun; 2017 Jan; 483(1):495-501. PubMed ID: 28007598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
    Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
    Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semisynthesis of ent-norstrobane diterpenoids as potential inhibitor for factor Xa.
    Wang J; Ma H; Fu H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3813-3815. PubMed ID: 30340898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1.
    Schweinitz A; Stürzebecher A; Stürzebecher U; Schuster O; Stürzebecher J; Steinmetzer T
    Med Chem; 2006 Jul; 2(4):349-61. PubMed ID: 16848746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.